While the SPX Index fell last week, the VIX Index also declined, in an unusual “spot down, vol down” move. COR1M Index gained ...
Mark Najarian from Thermo Fisher Scientific, talks to Neil Tyler about the company's role in semiconductor fabrication.
MOOD uses a 'black box' methodology, rebalancing weekly based on institutional versus retail sentiment. Find out why MOOD ETF ...
Introduction The massive growth in AI-electricity demand at data centers has sparked growing concern about rising electricity demand and ...
A new column examines how premium airline capacity can help identify the most promising business aviation corridors from the ...
CoinEx explains why Bitcoin may move beyond halving cycles, with institutions, liquidity, and selective capital shaping 2026.
Shallem, Greg Ravikovich and Eitan Har-Shoshanim examine how AI addresses the challenge of data overload in solar PV.
G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...
A man breached Windsor Castle with a crossbow after his large language model (LLM)-based companion encouraged an assassination plan. A father’s question about pi evolved into more than 300 h of ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results